We are delighted to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2021, which will take place from 5 to 8 May 2021.
#O2 Date: 07.05.2021, Lecture Time: 15:03 - 15:13, Session: Proffered Paper session 1
Speakers: A. Llop-Guevara (Barcelona, Spain)
Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
Llop-Guevara A, Vladimirova V, Schneeweiss A, et al.
Mini oral presentation #95MO Date: 08.05.2021 Lecture Time: 12:45 - 14:00, Session: Mini Oral session 2
Speakers: E. Laakmann (Hamburg, Germany)
Characteristics of patients with brain metastases from HER2-positive breast cancer
Laakmann E, Witzel I, Neunhöffer T, et al.
Date: 05.05.2021Session: ePoster Display Session
#17P Impact of body mass index (BMI) on prognostic and predictive value of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): a pooled analysis of six neoadjuvant trials.
Furlanetto J, Denkert C, Untch M, et al.
#21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)
Vladimirova V, Schneeweiss A, Jackisch C, et al.
#28P EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Leichsenring J, Vladimirova V, Solbach C, et al.
#66P Baseline menopausal status, Ki-67 and stromal tumor-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): exploratory analysis in GeparSixto
Labidi-Galy I, Schneeweiss A, Sinn HP, et al.